Comprehensive Genomic Profiling (CGP) helps maximize the ability to detect actionable genomic alterations. In one test, CGP addresses Growing number of biomarkers, increasing number of molecularly matched therapies and limited tissue biopsy. Find out more with our helpful infographic.
Download InfographicKey Benefits of CGP
Detect Multiple Biomarkers in a Single Assay —
CGP can detect all genomic variant classes such as:
Single Nucleotide Variants (SNVs)
InDels
Copy Number Variants (CNVs)
Gene Fusions
Splice Variants
Additionally, CGP can detect complex genomic signatures:
TMB
Tumor Mutational Burden
MSI
Microsatellite Instability
HRD
Homologous Recombination Deficiency
Current patient care relies on multiple biomarker testing, with often limited sample material. Comprehensive genomic profiling (CGP) is a NGS approach that identifies genomic alterations across hundreds of clinically relevant cancer biomarkers in a single assay and has the potential to replace the need to run multiple independent tests, including an HRD only test.
HRD status may reflect tumors positive for BRCA status and/or with a high GIS but does not address genomic variants beyond these factors. In these cases, CGP has the potential to identify biomarkers that may match patients with approved therapies or open clinical trials. HRD assessment and CGP together may decrease lab costs and time to answer, potentially improving patient outcomes.
Identify Actionable Alterations
CGP can detect actionable and emerging biomarkers to help identify more effective therapeutic and clinical trial options. Liquid biopsy CGP can be used as an alternative in the case that tissue is not available. Additionally, CGP from tissue and liquid biopsy samples together may reveal more insights into the alterations driving tumor growth and progression.6,7
Upgrade your browser or select an alternate
Chrome
Firefox
Safari
Edge